Brain Canada Brain Canada
FR Donate

Our directory of funded grants

311 result(s) found

Decoding the RNA stability programs that determine cell identity and function in human brain and neurodegenerative disorders

Project Overview

The brain cells in Alzheimer’s disease patients differ extensively from healthy brain cells at the molecular level: there are hundreds of genes that are normally active in the brain, but become inactive in Alzheimer’s. Similarly, Alzheimer’s disease appears to turn on hundreds of genes that ar…

See researchers on this project
Principal Investigator:
  • Hamed Najafabadi, McGill University

Defining conserved functions of RNA binding proteins in stress-granule biogenesis

Project Overview

RNA is a mobile form of genetic information that is made from our DNA and its complex regulation is extremely important to the proper functioning of our cells. Since the discovery of TDP-43 in 2006 as a substance that plays a major role in ALS, the hypothesis that abnormal regulation of RNA is criti…

See researchers on this project
Principal Investigator:
  • Eric Lecuyer, Institut de Recherches Cliniques de Montréal, Université de Montréal

Detection and prevention of pypermutant glioma in children and young adults

Project Overview

Need for project: Replication repair deficiency (RRD) is a genetic condition that significantly increases the risk of developing cancer, particularly early in life. Gliomas are the most common brain tumour seen in children and young adults (CAYA), and occur frequently in RRD. Currently, the prevalen…

See researchers on this project
Principal Investigator:
  • Uri Tabori, The Hospital For Sick Children
Team Members:
  • Cynthia Hawkins, The Hospital For Sick Children
  • Jane Barron, Memorial University
  • Sunit Das, St. Michael's Hospital
  • Sidney E. Croul, Dalhousie University
  • Birgit Ertl-Wagner, The Hospital for Sick Children
  • Andrew Gao, University Health Network
  • Normand J Laperriere, Princess Margaret Cancer Centre
  • Julia Keith, Sunnybrook Health Sciences Centre
  • Farzad Khalvati, The Hospital for Sick Children
  • Derek Tsang, Princess Margaret Cancer Centre - UHN

Detection of misfolded TDP-43 in CSF of ALS cases: Diagnostic potential of confirmation-specific antibodies

Project Overview

A more streamlined way to diagnose ALS earlier is desperately needed as current methods can take up to two years and rely heavily on ruling out other conditions that share similar symptoms. One of the hallmarks of ALS for 97 per cent of cases is the accumulation of misfolded TDP-43 protein in motor …

See researchers on this project
Principal Investigator:
  • Yulong Sun, University Health Network (University of Toronto)

Detection of tandem repeat expansion in neurological disorders

Project Overview

In the past decade, rapid development of software has allowed detection of a wide variety of genetic risk factors in brain disorders. It has improved clinical diagnosis and gene discovery for numerous human brain disorders. However, the casual genetic risk factors identified so far generally confer …

See researchers on this project
Principal Investigator:
  • Ryan Yuen, The Hospital for Sick Children

Development and validation of reagent kits for commercial high-throughput screening of PPI s and PPI inhibitors

Project Overview

Membrane proteins, which make up approximately one-third of all proteins in a cell, are responsible for a variety of processes, making them attractive therapeutic targets for many diseases such as hypertension, diabetes, neurological disorders and cancer. Understanding membrane protein function depe…

See researchers on this project
Principal Investigator:
  • Igor Stagljar, University of Toronto

Development of a high throughput 3D microphysiologicalplatform for rapid automated assessment of human brain organoids response to drugs targeting neurological disorders

Project Overview

Alzheimer’s disease (AD) and Parkinson’s disease (PD) are the most common and devastating neurological diseases, with over 750,000 AD patients and over 100,000 PD patients in Canada. Drug development remains a slow, expensive and inefficient process. The biopharmaceutical industries need alterna…

See researchers on this project
Principal Investigator:
  • Thomas Durcan, Montreal Neurological Institute and Hospital, McGill University
Team Members:
  • Edward Fon, McGill University
  • Margaret Magdesian, ANANDA Devices
  • Christopher Moraes, McGill University

Development of novel oligonucleotide delivery modalities for Huntington disease

Project Overview

Huntington disease (HD) is an inherited neurodegenerative disease that affects approximately 1 in 7500 individuals in the Western world. The cause of HD is a mutation in one copy of the HTT gene, which produces the toxic mutant huntingtin protein responsible for the brain cell loss associated with t…

See researchers on this project
Principal Investigator:
  • Blair Leavitt, University of British Columbia
Team Members:
  • Danica Stanimirovic, National Research Council of Canada
  • Abedelnasser Abulrob, National Research Council of Canada
  • Jodi McBride, Oregon Health and Science University

Developmental origins of stress and self-regulation and implications for interventions to improve childhood behavior

Project Overview

Dr.  Neuenschwander’s research aims to explore how exposure to stress during pregnancy affects children’s development, specifically in relation to children whose mothers were depressed and/or on antidepressants during pregnancy. She is examining whether or not these children have problems later…

See researchers on this project
Principal Investigator:
  • Regula Neuenschwander, Child & Family Research Institute

Direct microglial reprogramming to study Parkinson’s Disease

Project Overview

The human brain is a complex organ that presents many challenges for neuroscientists. For instance, tissue availability represents a major problem given that this organ does not regenerates, making it next to impossible to obtain live tissue from patients that would allow to study how cells in the b…

See researchers on this project
Principal Investigator:
  • Janelle Drouin-Ouellet, University of Montreal

Discovery of Therapeutic Targets for FUS- and TDP43-Dependent Forms of ALS

Project Overview

The four most commonly studied ALS proteins are SOD1, TDP-43, FUS and C9ORF72. Of these, TDP-43 and FUS have the most in common. Not only do they share similar functions inside cells, but in motor neurons of people with ALS, they both accumulate in clumps outside of the area where they are supposed …

See researchers on this project
Principal Investigator:
  • Peter St. George-Hyslop, University of Toronto
Team Members:
  • Mei Zhen, Lunenfeld-Tanenbaum Research Institute, Mount Sinani Hospital
  • Peter Roy, University of Toronto
  • Ben Wolozin, Boston University
  • Clemens Kaminski, University of Cambridge

Discovery of transcriptomic biomarkers and epigenetic therapeutic targets for c9ALS and sALS

Project Overview

Dr. Belzil began her research career as a PhD student at the Université de Montréal under the guidance of world renowned geneticist and Director of the Montreal Neurological Institute and Hospital, Dr. Guy Rouleau. During this time, Dr. Belzil pursued a better understanding of the genetics behind …

See researchers on this project
Principal Investigator:
  • Veronique Belzil, Mayo Clinic

Disrupted SUMOylation facilitates rogue TDP-43 in ALS

Project Overview

Proteins are large molecules that play many essential roles in the body. They do most of the work inside cells and are necessary for the structure, function and regulation of all tissues and organs. TDP-43 is a protein that is usually found inside the cell nucleus. However, in most people with ALS, …

See researchers on this project
Principal Investigator:
  • Terry Suk, University of Ottawa

Dissecting acetylcholine/glutamate co-transmission in the striatum: importance of individual neurotransmitter in addiction and movement disorders

Project Overview

Parkinson’s disease and addiction have tremendous human and economical costs for our society. The secret to understand these pathologies lies in unravelling the functioning of a specific brain region named striatum. The striatum regulates several behavioural outputs that are affected in Parkinson…

See researchers on this project
Principal Investigator:
  • Salah El Mestikawy, Douglas Mental Health University Institute
Team Members:
  • Vania Prado, University of Western Ontario
  • Marco Prado, University of Western Ontario

Distinct neuro-immune interactions drive sex differences  in chronic pain

Project Overview

One of the most important advances in our understanding of chronic pain over the last decade or so is the realization that neurons are not the only cells in the central nervous system participating in the processing of pain signals. Immune-like “glial” cells (especially microglia and astrocytes)…

See researchers on this project
Principal Investigator:
  • Jeffrey Mogil, McGill University
Team Members:
  • Michael Salter, The Hospital for Sick Children
  • Yves De Koninck, Université Laval
  • Jason Lerch, University of Toronto

DNA methylation signatures in a rat model of Fetal Alcohol Spectrum Disorder

Project Overview

Prenatal alcohol exposure can result in abnormal brain development, causing Fetal Alcohol Spectrum Disorder (FASD), which is linked to a number of cognitive, behavioural, and immune deficits that last across the lifetime. Although the lasting effects of alcohol on development are well studied, the m…

See researchers on this project
Principal Investigator:
  • Alexandre Lussier, University of British Columbia

Does rehabilitation improve brain structure/function and motor outcomes of children with developmental coordination disorder?

Project Overview

Ms. Izadi-Najafabadi’s research focuses on the effect of Cognitive Orientation to Occupational Performance (CO-OP)—the current best-practiced intervention for children with Developmental Coordination Disorder (DCD)—on their structural and functional brain connectivity. This study also explores…

See researchers on this project
Principal Investigator:
  • Sara Izadi-Najafabadi, Brain Research Centre, University of British Columbia

Dopaminergic modulation of stroke recovery

Project Overview

Strokes often cause brain damage that affects normal cognitive and sensorimotor functions. The brain has the extraordinary ability to adapt by forming new circuits which can, to some extent, compensate for neuronal loss. The recovery of motor function can be improved by rehabilitation exercises aime…

See researchers on this project
Principal Investigator:
  • Christian Ethier, Université Laval

Douglas-Bell Canada Brain Bank, an essential platform for brain research in Canada

Project Overview

The Douglas-Bell Canada Brain Bank (DBCBB) houses and manages over 3,000 brains, as well as a large relational database containing demographic, clinical and developmental histories from the donors. The DBCBB is one of the rare brain banks in the world to collect brains from people who suffered from …

See researchers on this project
Principal Investigator:
  • Gustavo Turecki, Douglas Hospital Research Centre
Team Members:
  • Naguib Mechawar, Douglas Mental Health University Institute
  • Michael J. Meaney, Douglas Mental Health University Institute
  • Guy Rouleau, Montreal Neurological Hospital and Institute
  • Michael Kobor, University of British Columbia
  • Martin Alda, Dalhousie University
  • Paul R. Albert, Ottawa Hospital Research Institute
  • Cathy Barr, Toronto Western Hospital
  • Darrell Mousseau, University of Saskatchewan
  • Satyabrata Kar, University of Alberta
  • Shimon Amir, Concordia University
  • Ana Andreazza, Centre for Addiction and Mental Health
  • Gilbert Bernier, Research Centre, Maisonneuve-Rosemont Hospital
  • Diane Boivin, Douglas Mental Health University Institute
  • Bernard Brais, Montreal Neurological Hospital and Institute
  • Nicolas Cermakian, Douglas Mental Health University Institute
  • Balu Chakravarthy, Carleton University
  • Cletus D’Souza, BC Cancer Agency
  • Salah El Mestikawy, Douglas Mental Health University Institute
  • Carl Ernst, Douglas Mental Health University Institute
  • Ken Evans, Queen's University
  • Harriet Feilotter, Queen's University
  • Nicolas Flamand, Institut Universitaire de Cardiologie et Pneumologie de Quebec, Laval University
  • Cecilia Flores, Douglas Mental Health University Institute
  • David Fortin, Université de Sherbrooke
  • Edith Hamel, Montreal Neurological Hospital and Institute
  • Michael R. Hayden, University of British Columbia
  • Sébastien Hébert, CHUQ Research Centre, Laval University
  • Martin Hirst, BC Cancer Agency
  • Jack Jhamandas, University of Alberta
  • Sidney H. Kennedy, University Health Network
  • Christine Lavoie, Université de Sherbrooke
  • Marco Marra, BC Cancer Agency
  • Anne McKinney, McGill University
  • Daniel Mueller, Centre for Addiction and Mental Health
  • Gerhard Multhaup, McGill University
  • Lisa Münter, McGill University
  • Art Petronis, University of Toronto/CAMH
  • Bruce Pike, Montreal Neurological Hospital and Institute
  • Judes Poirier, Douglas Mental Health University Institute
  • Alexandre Prat, CHUM Research Centre, University of Montréal
  • Rémi Quirion, Douglas Mental Health University Institute
  • Pedro Rosa-Neto, Douglas Mental Health University Institute
  • Xavier Roucou, Université de Sherbrooke
  • Elizabeth Simpson, University of British Columbia
  • Abbas Sadikot, Montreal Neurological Hospital and Institute
  • Lalit Srivastava, Douglas Mental Health University Institute
  • Moshe Szyf, McGill University
  • Derek van der Kooy, University of Toronto
  • Christine Vande Velde, Université de Montréal
  • Lan Xiong, CHUM Research Centre, University of Montréal
  • L. Trevor Young, Centre for Addiction and Mental Health

Drug Delivery across the Human Blood-Brain Barrier

Project Overview

Toxic amyloid proteins are known to be a significant contributing factor in the development of Alzheimer’s disease. Abnormal clusters of protein fragments build up between nerve cells in the brainleading to impaired memory. The most important therapies in development currently are biologics, antib…

See researchers on this project
Principal Investigator:
  • Nathan Yoganathan, KalGene Pharmaceuticals Inc
Team Members:
  • Louis Collins, McGill University
  • Jean-Paul Soucy, McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University
  • Danica Stanimirovic, National Research Council of Canada
  • Balu Chakravarthy, Carleton University
  • Pedro Rosa-Neto, Douglas Mental Health University Institute